Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SVIL antisense RNA 1 (SVIL-AS1)
- Target
- SVIL-AS1
- Molecular classification
- Long noncoding RNA (lncRNA), Antisense RNA
01
Overview
SVIL antisense RNA 1 is a long noncoding antisense RNA located on chromosome 10q13. It is downregulated in lung adenocarcinoma tissues and correlates with better patient prognosis. Functionally, SVIL-AS1 restrains proliferation and promotes cell cycle arrest in lung adenocarcinoma cells by facilitating the proteasomal degradation of E2F1, a key cell cycle regulator. The RNA methyltransferase METTL3 installs m6A methylation marks on SVIL-AS1, increasing its stability and enhancing its tumor-suppressive activity. The mechanism links m6A-modified lncRNA function with regulation of cell cycle and cancer progression.
- Other names
- RP11-534G20.3SVIL-AS1
02
Mechanism of action
For experimental manipulations, SVIL-AS1 acts by increasing its expression (via METTL3-mediated m6A RNA methylation) to suppress proliferation and promote cell cycle arrest, mediated through degradation of E2F1 and downregulation of its target genes
03
Biological functions
Regulation of gene expression (asRNA function)Cell cycle arrest (G1 phase block)Inhibition of cell proliferationPromotion of E2F1 protein degradation via the ubiquitin-proteasome pathway
04
Disease associations
Cancer, specifically lung adenocarcinoma (LUAD)
05
Safety considerations
Therapeutic targeting of lncRNAs may present challenges such as off-target effects, delivery specificity, and reliance on RNA modification pathways (e.g., METTL3/m6A methylation)Specific safety data for SVIL-AS1 targeting are lacking
06
Interacting drugs
No approved drugs or investigational compounds directly targeting SVIL-AS1 have been described in the current literature. Its modulation is achieved experimentally through RNA interference or genetic overexpression.
07
Biomarkers
SVIL-AS1 expression level (downregulated in LUAD—associated with favorable prognosis)
Beyond the preview
Go deeper on SVIL antisense RNA 1 (SVIL-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SVIL antisense RNA 1 (SVIL-AS1).